Sign In
Buy GLYC
$15.71
+0 (+0%)
At Close: Oct 01, 2025
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics' (Nasdaq: GLYC) product candidate uproleselan — when added to a combination therapy of venetoclax and a hypomethylating agent (HMA) — was shown today
GlycoMimetics' (GLYC) CEO Rachel King on Q3 2020 Results - Earnings Call Transcript
11:18am, Friday, 06'th Nov 2020
GlycoMimetics' (GLYC) CEO Rachel King on Q3 2020 Results - Earnings Call Transcript
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2020
07:30am, Friday, 06'th Nov 2020
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the third quarter ended September 30, 2020, and highlighted recent company events. Cash and
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that three abstracts including data from the Company's clinical and research portfolio have been accepted for oral p
GlycoMimetics to Report Third Quarter Financial Results on November 6, 2020
09:00am, Friday, 30'th Oct 2020
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its third quarter financial results on Friday, November 6,
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that new post hoc analyses of the Phase 3 RESET study evaluating the efficacy of rivipansel, its wholly-owned produc
Bank Efficiency Ratio: The Carl Perkins Of Bank Due Diligence
05:30pm, Sunday, 04'th Oct 2020
Bank efficiency ratios are an effective and easy means of comparing management’s ability to control overhead.
Major Asset Classes Under Pressure In September
12:00am, Thursday, 01'st Oct 2020
Market Overview Analysis by James Picerno covering: iShares Russell 3000 ETF. Read James Picerno's latest article on Investing.com
Galectin Therapeutics Inc. (NASDAQ:GALT) Director Kevin D. Freeman Acquires 5,000 Shares
06:50am, Thursday, 10'th Sep 2020
Galectin Therapeutics Inc. (NASDAQ:GALT) Director Kevin D. Freeman acquired 5,000 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was purchased at an average p
Global Hemoglobinopathy Treatment Drugs Market to Surpass US$ 6.4 Billion by 2027, Says Coherent Market Insights
12:00am, Tuesday, 11'th Aug 2020
The global hemoglobinopathy treatment drugs market is projected to exhibit a CAGR of 8.4% during the forecast period (2020-2027).
ConveGenius Acquires Gray Matters To Boosts AI-Based Assessment Products
02:09pm, Monday, 10'th Aug 2020
The step has been taken to further strengthen ConveGenius' - EdTech for Naya Bharat campaign that aims to empower 100 million students at the bottom of the education funnel
3 “Strong Buy” Healthcare Stocks Under $5 That Could See Outsized Gains
09:19pm, Thursday, 06'th Aug 2020
The stock market just keeps going up, up and away. COVID-19 continues to have a choke hold on the economy, yet stocks have pulled off an incredible recovery, with the S&P 500 up 50% since its March lo
Risk Premia Forecasts: Major Asset Classes - 4 August 2020
12:08am, Wednesday, 05'th Aug 2020
The long-run risk premia estimate for the Global Market Index ticked higher again in July, edging up to 4.8%.
Risk Premia Estimate For Global Market Index Ticks Higher
12:00am, Tuesday, 04'th Aug 2020
Market Overview Analysis by James Picerno covering: . Read James Picerno's latest article on Investing.com
Introducing GMI, Merging 80 Years of IT Solutions Experience to Address Critical Customer Challenges
12:00am, Monday, 03'rd Aug 2020
Today marks the official launch of GMI (Global Market Innovators), one of the largest women- and minority-owned Information Technology Solutions compa
